Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical (Takeda) has received notice of sanctions imposed by the Japan Pharmaceutical Manufacturers Association (JPMA) for promotional activities regarding Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J).
Subscribe to our email newsletter
The sanctions against the company relate to part of its promotional activities regarding CASE-J which were inviolation of the ‘Prescription Drugs Promotion Code’ of the JPMA and as a result, the company’s activities as vice president of the JPMA will be temporarily suspended for six months, effective 03 April 2014.
JPMA is imposing sanctions against the company because of the promotional activities in Japan that continued after January 2007 to refer to CASE-J study data presented at the International Society for Hypertension, without replacing such data in promotional materials for candesartan after the publication of the academic paper describing the CASE-J study results.
Currently, a third-party investigation related to CASE-J activities of Takeda is being carried out and the company is fully cooperating with a third-party investigation initiated to examine this incident.
The company takes this sanction imposed by the JPMA very seriously, and sincerely apologizes to all stakeholders including patients and healthcare professionals for the concern caused by its actions.
To both prevent similar incidents in the future and to further enforce preventive measures, the company is continuing to fully cooperate with the ongoing third-party investigation into all of its promotional activities to identify areas requiring improvement.